6 results
The objective of this study is to determine whether influencing the protein pathway thought to underlie TSC by Everolimus treatment will improve cognitive abilities in these children.
Primary objective* To evaluate the efficacy in terms of overall survival (OS) of erlotinib, everolimus and dasatinib in combination with radiation therapy, in patients with a DIPG both: - compared to the other experimental treatments by comparisons…
Main objective:To improve the functional neurological outcome of patients, as measured on the Raschbuilt Overall Disability Scale (RODS) for inflammatory neuropathies (iRODS) with Zanubrutinib in combination with standard treatment with Rituximab or…
To prove that the RECAP test has the potential of selecting patients who are sensitive to treatment with the PARP inhibitor talazoparib as measured by the PFS rate at 4 months.
To evaluate the long-term safety of zanubrutinib in patients with B-cell cancers who participated in a BeiGene parent study for zanubrutinib
Primary:• To compare the efficacy of zanubrutinib (also known as BGB-3111) versus ibrutinib as measured by overall response rate determined by investigator assessment Secondary:• To compare the efficacy of zanubrutinib versus ibrutinib as measured…